Showing results (151-160 of 178) with videos related to
Sort By:
Pageof 18
Neuro-Oncology|July 7, 2023
Randomized phase III trial of metabolic imaging-guided dose escalation of radio-chemotherapy in patients with newly diagnosed glioblastoma (SPECTRO GLIO trial)Anne Laprie, Georges Noel, Leonor Chaltiel, et al.BMC Cancer|February 23, 2019
Dose-painting multicenter phase III trial in newly diagnosed glioblastoma: the SPECTRO-GLIO trial comparing arm A standard radiochemotherapy to arm B radiochemotherapy with simultaneous integrated boost guided by MR spectroscopic imagingAnne Laprie, Soléakhéna Ken, Thomas Filleron, et al.The Lancet. Oncology|March 8, 2021
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trialJoël Guigay, Anne Aupérin, Jérôme Fayette, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2020
PD-1 Blockade in Anaplastic Thyroid CarcinomaJaume Capdevila, Lori J Wirth, Thomas Ernst, et al.EMBO Molecular Medicine|May 25, 2021
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage componentBenoit Thibault, Fernanda Ramos-Delgado, Elvire Pons-Tostivint, et al.Journal for Immunotherapy of Cancer|August 6, 2024
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burdenMichael Schenker, Mauricio Burotto, Martin Richardet, et al.JAMA Oncology|September 28, 2023
Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled TrialTae Won Kim, Philippe L Bedard, Patricia LoRusso, et al.NPJ Precision Oncology|April 9, 2026
Terminal T-cell exhaustion predicts tumor control independent of immunotherapy in ovarian cancerAnna Salvioni, Marie Michelas, Mathilde Del, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 24, 2020
Neoadjuvant Nivolumab for Patients With Resectable Merkel Cell Carcinoma in the CheckMate 358 TrialSuzanne L Topalian, Shailender Bhatia, Asim Amin, et al.Cancer Discovery|April 2, 2017
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal CancerRobin M J M van Geel, Josep Tabernero, Elena Elez, et al.Pageof 18